Fmoc-D-Asn-OPfp

Fmoc-D-Asn-OPfp is an Fmoc-protected D-asparagine derivative bearing a C-terminal OPfp ester, where OPfp denotes the pentafluorophenyl (Pfp) ester that activates the carboxylate for subsequent peptide coupling. The molecule contains a stereogenic center at the D-asparagine backbone, an amide side chain (asparagine), and an orthogonally removable N-protecting group (Fmoc) that supports standard base-mediated deprotection in solid-phase or solution-phase peptide synthesis. The Pfp ester functionality enhances acyl-transfer reactivity relative to non-activated esters and can participate in peptide bond formation under coupling conditions compatible with Fmoc chemistry. The combination of a chiral amino acid scaffold, a protected N-terminus, and a highly reactive carboxyl-activated handle makes Fmoc-D-Asn-OPfp a targeted intermediate for building stereodefined D-amino acid-containing sequences and downstream derivatization.

1. Peptide Synthesis

Fmoc-D-Asn-OPfp is applied in peptide building workflows where Fmoc deprotection and subsequent amide bond formation are required for constructing D-asparagine-containing peptides and peptidomimetics. The Fmoc group controls N-terminus reactivity, while the D-asparagine stereochemistry is preserved to enable stereodefined incorporation into peptide chains that may resist proteolysis or alter backbone recognition. The OPfp ester serves as an activated carboxyl component that can undergo coupling to introduce the asparagine residue at a defined position, supporting both solution-phase and solid-phase assembly strategies. The resulting D-amino acid peptide products can be used as biochemical research tools, scaffold components, or analytical standards for studying sequence-dependent behavior in amino acid chemistry and peptide science.

2. Side-Chain Functionalization

Fmoc-D-Asn-OPfp supports amino acid derivatization strategies that leverage the asparagine side-chain amide for controlled chemical transformations after peptide incorporation or at the intermediate stage. The side-chain amide can be retained during peptide coupling to preserve hydrogen-bonding patterns, then can be converted to alternative functional motifs through subsequent functional group interconversions that maintain the D-configuration at the backbone. The presence of an Fmoc-protected amine allows orthogonal handling of the N-terminus during side-chain modification workflows, reducing cross-reactivity with the activated carboxylate. Downstream products derived from the D-asparagine scaffold can feed into fragment generation for structure-activity relationship studies, peptidomimetic design, and synthetic organic chemistry routes that require stereodefined amide-bearing intermediates.

3. Bioconjugation Chemistry

Fmoc-D-Asn-OPfp can be employed in chemical biology and bioconjugation efforts where a D-amino acid residue is incorporated into peptide linkers or conjugation handles to modulate stability and binding characteristics. The activated OPfp ester enables formation of amide linkages to nucleophilic partners under coupling-compatible conditions, while the Fmoc group provides a protected nitrogen that can be removed to expose a reactive amine when needed for subsequent conjugation steps. The D-asparagine backbone offers a stereochemical control element that can influence linker conformation and recognition by biomolecules, supporting the construction of defined conjugates for assay development. The resulting D-amino acid-containing conjugation reagents can be used to generate labeled biomolecular probes, peptide-based affinity reagents, or modular components for studying molecular interactions in applied biochemical research.

4. Chiral Building Block Development

Fmoc-D-Asn-OPfp is suitable for chiral synthesis programs that require a protected D-amino acid intermediate with an activated carboxyl terminus for reliable peptide coupling chemistry. The D-stereocenter and the asparagine side-chain amide provide a defined three-dimensional scaffold that can be transferred into target sequences without racemization, supporting stereochemical integrity in downstream analog construction. The orthogonal combination of Fmoc protection and Pfp ester activation enables controlled deprotection and coupling operations, aligning with strategies used to prepare stereochemically pure peptide building blocks for research-grade synthesis. The compound can therefore serve as a practical chiral precursor for manufacturing and fine chemical synthesis of D-amino acid-containing intermediates used in peptide science, peptidomimetics, and stereodefined molecular design.

5. Pharmaceutical Manufacturing

Fmoc-D-Asn-OPfp is relevant to industrial peptide intermediate preparation where Fmoc-protected amino acid derivatives and activated esters are used to construct consistent, stereochemically defined sequences for downstream drug discovery and process development. The Fmoc group supports standardized deprotection logic, while the OPfp ester provides a coupling-ready carboxyl functionality that can be integrated into controlled manufacturing routes for peptide building blocks. The D-asparagine scaffold may be incorporated into peptide-like intermediates to tune stability and sequence properties during process development, enabling the production of defined stereochemical variants for analytical and synthetic campaigns. The compound's compatibility with established amino acid coupling paradigms makes it applicable to specialty chemical production and pharmaceutical intermediate synthesis where robust peptide construction steps are required.

1. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

2. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

3. TMEM16F and dynamins control expansive plasma membrane reservoirs

4. Myotropic activity of allatostatins in tenebrionid beetles

5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis